Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2011

View Archived Issues

S-44563 assessed in vivo in models of uveal melanoma

Full results reported from phase II trial of aldosterone synthase inhibitor in primary hypertension

Promising in vivo data presented on BI-853520

Mutant-selective inhibitor of epidermal growth factor receptor assessed in NSCLC

Boehringer Ingelheim discloses preclinical data on MAb targeting insulin-like growth factor I and II

Lilly describes antitumor effects of dual cyclin-dependent kinase inhibitor

Cel-Sci updates status of phase III Multikine trial

Immunomedics provides overview of development activities 2011

Hand, foot and mouth disease vaccine is safe and immunogenic

Sanofi discloses new histamine H3 receptor inverse agonists

Janssen begins phase II CNTO-1959 trial with milestone payment to MorphoSys

Novel phosphodiesterase 10A inhibitors synthesized by Amgen

Fuso withdraws Japanese application for buprenorphine buccal adhesive

Theravance begins proof-of-concept study of new candidate ADHD therapy

Kissei to transfer distribution rights for Parkinson's disease treatment

European Commission approves product for CDI-associated diarrhea

Health Canada approves treatment for iron deficiency anemia in CKD

Medical Research Council Technology patents novel protein kinase inhibitors

Data and safety monitoring board recommends continuation of vosaroxin trial

Abbott and Reata Pharmaceuticals enter new collaboration agreement

Ono and Receptos join to discover novel GPCR-targeted therapeutics

Mochida out-licenses type 2 diabetes treatment candidates

Dako collaborates with Genentech on companion diagnostics for pertuzumab

First Nanobody for inhalation enters clinic

NIDA to fund study of Biotie's nepicastat

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...